https://www.polity.org.za
Deepening Democracy through Access to Information
Home / Speeches RSS ← Back
Close

Email this article

separate emails by commas, maximum limit of 4 addresses

Sponsored by

Close

Embed Video

SA: Tshabalala-Msimang: Meeting on suspended HIV vaccine trials (14/11/2007)

14th November 2007

SAVE THIS ARTICLE      EMAIL THIS ARTICLE

Font size: -+

Date: 14/11/2007
Source: Department of Health
Title: SA: Tshabalala-Msimang: Meeting on suspended HIV vaccine trials

Minister's meeting with principal investigators of HIV vaccine trials in South Africa

Ladies and gentlemen I wish to welcome you to the Department of Health and thank you for honouring this invitation in such a short notice. I called you today to brief me on the Phase II HIV vaccine clinical trial that was jointly conducted by the South African Aids Vaccines Initiative (SAAVI) and the HIV Vaccine Trials Network (HVTN) and was put on hold on Friday 21 September 2007.

Advertisement

In this meeting I would like us to have a discussion on this trial and others that have experienced difficulties by way of understanding the implications for future research. I am really concerned about the clinical trials that are started and then stopped for safety reasons. It is a particular concern as this has now happened more than once.

As I have a responsibility for the health and safety of the South African public, I am often asked to answer questions on this issue.

Advertisement

You will recall the following:

* In 2000, a large full-scale nonoxynol-9trial showed to be unsafe when it had been expected to be effective. Women in that trial developed a higher incidence of HIV infection, presumably through ulcers caused by chemical irritation.

* This year the Data and Safety Monitoring Board (DSMB) stopped the Cellulose Sulphate microbicide trial. This particular trial received attention at the Sydney Conference this year. Issues that were raised related to whether is it still necessary to continue with microbicides trials given the rate of failure in preventing the transmission of HIV and the resources that go into such trials.

* This HVTN 503 vaccine trial was placed on hold following a regularly scheduled meeting of the Independent Data and Safety Monitoring Board. This was after the DSMB had reviewed safety data and results of an interim efficacy analysis of the study. The DSMB felt that information available did not show that the vaccination would meet efficacy endpoints.

* I have been informed that the HVTN 503 study began enrolling and vaccinating participants in January 2007. Since that time, 799 individuals had been enrolled and 55 were fully immunised. The study was being conducted at five sites in Soweto, Cape Town, Klerksdorp, Pretoria and Durban.

* I therefore wish to hear what happened with this HVTN 503 trial?

* What measures have you taken thus far since the trial was stopped?

* Where are the clinical trial participants and what is happening to them?

* What other processes and activities are you undertaking regarding this trial?

* I also wish that the President of the Medical Research Council should input first into the discussion as he is in charge of SAAVI.

My questions to you this morning is:

* To what extent is the evidence from Phase I and Phase II studies that the intervention is safe?
* Secondly, has there been sufficient preparation ahead of initiating these studies. Why are we seeing a more frequent discontinuation of studies?
* How are we responding to the debates that took place among scientists at the Sydney conference and other scientific literature?
* And, what is the broader implication. How should we structure future studies in such a way that is does not raise public concerns and begin to undermine the confidence that the public have in these studies.

I trust that we will have an open and constructive discussion this morning.

Thank you

Issued by: Department of Health
14 November 2007

 


EMAIL THIS ARTICLE      SAVE THIS ARTICLE      FEEDBACK

To subscribe email subscriptions@creamermedia.co.za or click here
To advertise email advertising@creamermedia.co.za or click here


About

Polity.org.za is a product of Creamer Media.
www.creamermedia.co.za

Other Creamer Media Products include:
Engineering News
Mining Weekly
Research Channel Africa

Read more

Subscriptions

We offer a variety of subscriptions to our Magazine, Website, PDF Reports and our photo library.

Subscriptions are available via the Creamer Media Store.

View store

Advertise

Advertising on Polity.org.za is an effective way to build and consolidate a company's profile among clients and prospective clients. Email advertising@creamermedia.co.za

View options

Email Registration Success

Thank you, you have successfully subscribed to one or more of Creamer Media’s email newsletters. You should start receiving the email newsletters in due course.

Our email newsletters may land in your junk or spam folder. To prevent this, kindly add newsletters@creamermedia.co.za to your address book or safe sender list. If you experience any issues with the receipt of our email newsletters, please email subscriptions@creamermedia.co.za